Hegedus, L. Et Al. 2018. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. DIABETES CARE , vol.41, no.3 , 620-622.

Hegedus, L., Sherman, S. I., Tuttle, R. M., von Scholten, B. J., Rasmussen, S., Karsbol, J. D., ... Daniels, G. H.(2018). No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. DIABETES CARE , vol.41, no.3, 620-622.

Hegedus, Laszlo Et Al. "No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial," DIABETES CARE , vol.41, no.3, 620-622, 2018

Hegedus, Laszlo Et Al. "No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial." DIABETES CARE , vol.41, no.3, pp.620-622, 2018

Hegedus, L. Et Al. (2018) . "No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial." DIABETES CARE , vol.41, no.3, pp.620-622.

@article{article, author={Laszlo Hegedus Et Al. }, title={No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial}, journal={DIABETES CARE}, year=2018, pages={620-622} }